Profile
Prof. Gopal C. Kundu has obtained his Ph.D. in Chemistry from Bose Institute, Kolkata, India (1989). He did his post-doctoral work at the Cleveland Clinic Foundation, University of Colorado, University of Wyoming, and the National Institutes of Health in USA in the area of cardiovascular research, inflammatory diseases and reproductive biology from 1989 to 1998. He joined as Scientist-D at National Centre for Cell Science (NCCS) in 1998 and then promoted to Scientist-E, - F and G. His area of research at NCCS is tumor biology, cancer stem cells, tumor- stroma interaction, angiogenesis, cancer therapeutics biomarker development and nanomedicine. He has received several awards including Fellows Award for Research Excellence from NIH, USA; National Bioscience Award from DBT, New Delhi; Shanti Swarup Bhatnagar Prize from CSIR, New Delhi; International Award in Oncology from Greece; International Young Investigator Award from Mayo Clinic, USA and 7th National Grassroots Innovation Award from Rashtrapati Bhavan, India. He is Fellow of National Academy of Sciences and Indian Academy of Sciences. He has published 93 papers including Nature Medicine, Science, PNAS (USA), Cancer Research, J. of Invest. Dermatology, J. of Biol. Chem, Trends in Cell Biol., Oncogene, Nanomedicine (London), Molecular Cancer, Nanoscale, Carcinogenesis, EMBO Reports, BMC Cancer etc and one US patent and two Indian Patents (Provisional). He serves as Editorial Board Member of Current Molecular Medicine, Current Chemical Biology, Molecular Medicine Reports, American Journal of Cancer Research and Associate Editor of Molecular Cancer and Journal of Cancer Metastasis and Treatment (JCMT). Prof. Kundu is an Adjunct Visiting Professor at Curtin University, Perth, Australia. Recently, Prof. Kundu served as Dean, Acting Director and Director (i/c) at National Centre for Cell Science, Pune from 2018-2019. Currently, Prof. Kundu is Director, R&D of KIIT Deemed to be University (KIIT DU), Institute of Eminence, Bhubaneswar. Prof. Kundu has taken additional charge as Professor of Biotechnology, School of Biotechnology (KIIT DU) and Professor of Medicine and Molecular Research, Kalinga Institute of Medical Science (KIMS), KIIT DU.
H-index, i-10 index and total citations: h-index: 45, i-10 index: 78 and total citations: 6, 721
Research Interest
Prof. Gopal C Kundu’s laboratory is focused on high quality research in the area of Tumor Biology, Regulation of Gene Expression, Targeted Drug Delivery, Angiogenesis, Cancer Stem Cells, Chemical Biology and Nanotechnology. His group has primarily focused on understanding the biology of Osteopontin, a chemokine like ECM protein in various cancers including breast. His laboratory is extensively working in following areas for more than last 20 years. 1. Deciphering the role of Osteopontin (OPN) in tumor progression: Prof. Kundu’s group have dissected the molecular mechanisms by which Osteopontin (OPN) and its associated genes regulate the metastatic potential of breast and other cancers. A better understanding of mechanism by which OPN promotes tumorigenesis may be useful in crafting novel OPN-based anti-cancer therapy. The role of OPN in promoting cancer progression is the subject of in depth investigation. Thus, targeting OPN and its regulated signaling network could be a novel strategy to block tumor growth and angiogenesis and may develop an effective therapeutic strategy for the management of cancer. Figure No. 1 (Trends in Cell Biol, 2006, Expert Opin. Ther. Targets. 2007, 2010, 2014):
2. Cancer Stem Cells (CSCs) and their role in Tumor Growth and Metastasis: Tumor initiating cells having stem cell characteristics were first discovered in leukaemia and later in solid tumors that recently has become an important area in cancer research. These stem like tumor cells, termed as cancer stem cells (CSCs) govern tumor progression, angiogenesis and metastasis via modulating specific pathways that depends upon the type of the tissue. Prof. Kundu and group have recently shown that Notch1-MAPK signaling axis regulates CD133+ cancer stem cell-mediated melanoma growth, angiogenesis and lung metastasis and andrographolide, a druggable molecule suppresses CD133+ cancer stem cell-mediated lung metastasis in skin cancer. Fig. No. 2: (Kumar et al; Journal of Investigative Dermatology, 2016):
3. Role of tumor microenvironment in tumor progression: Tumor microenvironment consists of various cellular players including extracellular matrix (ECM), hypoxia, fibroblasts, neuroendocrine (NE) cells, adipose cells, immune-inflammatory cells and the lymphatic vascular networks. These components play crucial role in tumor growth, immune evasion, metastasis and angiogenesis. Earlier, Prof. Kundu and group have demonstrated the role of hypoxia and TAMs in Osteopontin regulated tumor progression in breast cancer and melanoma models respectively. Recently, our groups have explored how Tumor Activated Macrophages (TAMs) promotes cancer stem cell (CSC) phenotype and CSC-mediated breast tumor growth. Moreover, our group has studied how fibroblast differentiates into Myo fibroblast or Cancer Associated fibroblast (CAFs) and how that control breast tumor progression.
Fig. No. 3 (Raja et al, Oncogene, 2014; Kale et al, Oncogene, 2014)
4. Nanomedicine and Cancer Therapy: Breast cancer is a complex disease and most breast cancer treatments are limited to chemotherapy, radiation, and surgery. Substantial advances in breast cancer treatments have resulted in a significant decrease in mortality. However, existing breast cancer therapies often result in high toxicity and nonspecific side effects. Therefore, better targeted delivery and increased efficacy of drugs are crucial to overcome these effects. Application of nanotechnology or nanoparticle-mediated drug delivery can resolve some of these issues and these areas of research are expanding dramatically. Prof Kundu and group have synthesized and characterized cRGD peptide conjugated chitosan nanoparticles loaded with anticancer drug raloxifene or andrographolide. Enhanced uptake of Cy5.5 conjugated RGD CHNP was studied in triple negative and αvβ3 integrin over-expressing breast cancer cells. The decrease in cell viability was observed by MTT assay after treatment with drug- encapsulated nanoparticles. RGD conjugated nanoparticles exhibit enhanced inhibition of cell viability in these breast cancer cells. In vitro and in vivo toxicity studied revealed that these nano-drugs are not toxic in normal cells and tissues. Finally, Prof Kundu and his group have demonstrated that andrographolide or raloxifene encapsulated RGD-CHNPs significantly inhibited the breast tumor growth suggesting that RGD conjugated chitosan nanoparticles could be an effective approach for targeted therapeutic delivery in different sub-types of breast cancer.
Fig. No. 4: (Yadav et al,Nanoscale, 2020):
Future Research Plans
1. To establish breast, prostate, cervical, head and neck oral, gall bladder, colorectal and lung cancer specific Patient Derived Xenograft (PDX) models, develop primary cultures and cell lines from patients and PDX models and to identify potential therapeutic targets and therapeutically relevant biomarkers from cell lines, PDX and patients specimens using genomics and proteomics approaches. 2. To develop novel drugs and druggable agents by targeting cancer patients and PDX derived cancer stem cells, immune cells and stromal cells using chemical biology, nanotechnology and genetic approaches in breast and other cancers. 3. To establish innovative and technology driven translation research in the area of cancer, cardiovascular and other inflammatory diseases. 4. To train high class human resources including Ph.D. Students, Research Associate, Post-Doc and Project Students by providing high class research environment and research projects at the international level. 5. To establish high quality research collaboration at the national and international levels and to generate more research grants through national and international funding agencies.
Honors and Awards:
1. Shanti Swarup Bhatnagar Prize in Biological Sciences, Council of Scientific and Industrial Research (CSIR), New Delhi, Govt. of India, 2004 2. National Bioscience Award for Career Development, Dept. of Biotechnology (DBT), New Delhi, Govt. of India, 2003-04 3. Fellows Award for Research Excellence (FARE) from The National Institutes of Health (NIH), Bethesda, Maryland, USA (1997) 4. International Award for an outstanding achievement in Oncology, Greece, 2007 5. Platinum Jubilee Award Lecture, 99th Indian Science Congress Association, KIIT, Bhubaneswar, 2012 6. International Young Investigator Award, 5th Mayo Clinic Angiogenesis Symposium, USA 2012 7. 7th National Grassroots Innovation Award-2013, Rashtrapati Bhavan, New Delhi, 2013. 8. Adjunct Visiting Professor, Curtin University, Perth, Australia (2017-2020)
Professional Society Member/Fellow/Others:
1. Member of New York Academy of Sciences, USA (2000-2001) 2. Fellow of the National Academy of Sciences, India (2003) 3. Member of Guha Research Conference (GRC) (2003) 4. Fellow of the Indian Academy of Sciences (2006) 5. Member of American Society for Biochemistry and Molecular Biology, USA (2006) 6. Editorial Board Member of Current Molecular Medicine, USA (2006) 7. Editorial Board Member of Molecular Medicine Reports, Greece (2007) 8. Editorial Board Member of The Open Cancer Journal (2009) 9. Senior Editorial Board Member of American Journal of Cancer Research (2011) 10. Associate Editor, J. of Cancer Metastasis and Treatment (2015-) 11. Associate Editor, Molecular Cancer (IF: 10.69) (2015-)
Selected Publications
1. Kundu GC, Ji I, McCormick DJ, and Ji TH: Photoaffinity labeling of the lutropin receptor with synthetic peptide for carboxyl terminus of the human choriogonadotropina subunit. J. Biol. Chem. 271(19): 11063-11066, 1996. (I.F. 4.258) 2. Kundu GC, Mantile G, Miele L, Cordela-Miele E and Mukherjee AB: Recombinant human uteroglobin suppresses cellular invasiveness via a novel class of high-affinity cell surface binding site. Proc. Natl. Acad. Sci. USA 93: 2915-2919, 1996.(I.F. 9.423) 3. Kundu GC and Mukherjee AB: Evidence that porcine pancreatic phospholipase A2 via its high-affinity receptor stimulates extracellular matrix invasion by normal and cancer cells. J. Biol. Chem. 272(04), 2346-2353, 1997. (I.F. 4.258) 4. Zhang Z, Kundu GC, Yuan C-J, Ward JM, Lee EJ, DeMayo F, Westphal H and Mukherjee AB: Severe fibronectin-deposit renal glomerular disease in mice lacking uteroglobin. Science 276,1408-1412, 1997. (I.F. 34.661) 5. Kundu GC, Panda D, Lee BI, Peri A, Fohl D, Chackalaparampil I, Mukherjee BB, Li XD, Mukherjee DC, Seides S, Rosenberg J, Stark K and Mukherjee AB: Potential roles of osteopontin and avb3 integrin in the development of coronary artery restenosis after angioplasty. Proc. Natl. Acad. Sci. USA 94, 9308-9313, 1997. (I.F. 9.423) 6. Phang T, Kundu GC, Hong S, Ji I and Ji TH: The amino terminal region of the luteinizing hormone/choriogonadotropin receptor contacts both subunits of human choriogonadotropin: II Photoaffinity labeling. J. Biol. Chem. 273(22), 13841-13847, 1998. (I.F. 4.258) 7. Kundu GC, Zhang Z, Panda D, Mandal A.K., Mantile-SelvaggiPeri A, Yuan C-J and Mukherjee AB: Loss of transformed phenotype in cancer cells by over expression of uteroglobin gene. Proc. Natl. Acad. Sci. USA 96, 3963- 3968, 1999. (I.F. 9.423) 8. Kundu GC, Zheng F, Zhang Z, Ward JM, DeMayo F, Mukherjee AB: An essential role of uteroglobin in preventing immunoglobulin A-nephropathy in mice. Nature Medicine 5(9), 1018-1025, 1999. (I.F. 30.357) 9. Philip S, Bulbule, A and Kundu GC: Osteopontin stimulates tumor growth and activation of pro-matrix metalloproteinase-2 through NF-kappa B mediated induction of membrane type 1-matrix metalloproteinase in murine melanoma cells. J. Biol. Chem. 276 (48), 44926-44935, 2001. (I.F. 4.6) 10. Mahabeleshwar GH and Kundu GC: Syk, a protein tyrosine kinase, suppresses the cell motility and NF-kappa B mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3’-kinase activity in breast cancer cells. J. Biol. Chem. 278 (8), 6209-6221, 2003. (I.F. 4.6) 11. Philip S and Kundu GC: Osteopontin induces NF-kappa B mediated promatrix metalloproteinase-2 activation through IKK/I B signaling pathways and curcumin (diferulolylmethane) down regulates these pathways. J. Biol. Chem. 278 (16), 14487-14497, 2003. (I.F. 4.6) 12. Das R, Mahabeleshwar GH and Kundu GC: Osteopontin stimulates cell motility and NF- B mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J. Biol. Chem. 278 (31), 28593-28606, 2003. (I.F. 4.6) 13. Mahabeleshwar GH and Kundu GC: Tyrosine kinase, p56lck regulates cell motility and NF- B-mediated secretion of urokinase type plasminogen activator through tyrosine phosphorylation of I B following hypoxia/reoxygenation. J. Biol. Chem. 278 (52), 52598-52612, 2003. (I.F. 4.6) 14. Mahabeleshwar GH, Das R and Kundu GC: Tyrosine kinase, p56lck-induced cell motility and urokinase type plasminogen activator secretion involves activation of epidermal growth factor receptor/extracellular signal regulated kinase pathways. J. Biol. Chem. 279 (11), 9733-9742, 2004. (I.F. 4.6) 15. Rangaswami H, Bulbule A and Kundu GC: Nuclear factor inducing kinase plays crucial role in osteopontin induced MAPK/IKK dependent nuclear factor B-mediated promatrix metalloproteinase-9 activation. J. Biol. Chem. 279 (37), 38921-38935, 2004. (I.F. 4.3) 16. Das R, Mahabeleshwar GH and Kundu GC: Osteopontin induces AP-1- mediated secretion of urokinase type plasminogen activator through c-Src dependent EGF receptor transactivation in breast cancer cells. J. Biol. Chem. 279 (12), 11051-11064, 2004. (I.F. 4.3) 17. Rangaswami H, Bulbule A and Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends in Cell Biol. 16 (2), 79- 87, 2006.(I.F. 11.5) 18. Chakraborty G, Rangaswami R, Jain S, and Kundu GC: Hypoxia regulates crosstalk between Syk and Lck leading to breast cancer progression and angiogenesis.J. Biol. Chem. 281 (16), 11322-11331, 2006. (I.F. 4.6) 19. Jain S, Chakraborty G and Kundu GC: The Crucial Role of cyclooxygenase-2 in osteopontin-induced PKCα/c-Src/IKKα/β dependent prostate tumor progression and angiogenesis. Cancer Res. 66 (13), 6638-6648, 2006. (I.F. 9.3) 20. Chakraborty G, Jain S and Kundu GC:Osteopontin promotes VEGF dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 68 (1),152-161, 2008. (I.F. 9.3) 21. Jain S, Chakraborty G, Raja R, Kale S, and Kundu GC: Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res, 68(19):7750– 7759, 2008. (I.F. 9.3) 22. Sharma P, Kumar S and Kundu GC: Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells. Molecular Cancer, July 7, 9(1), 178, 2010.(I.F. 6.2) 23. Kumar V, Behera R, Lohite K, Karnik S and Kundu GC: p38 Kinase is Crucial for Osteopontin-induced Furin Expression that Supports Cervical Cancer Progression. Cancer Research, 70 (24), 10381-10391, 2010.(I.F. 9.3) 24. Raja R, Kale S, Thorat D, Gowrishankar S, Lohite K, Mane A, Karnik S, Kundu GC:Hypoxia driven osteopontin contributes to breast tumor progression through modulation of HIF1α-mediated VEGF dependent angiogenesis.Oncogene. 2014 Apr 17;33(16):2053-64. doi: 10.1038/onc.2013.171. Epub 2013 Jun 3.(I.F. 8.6) 25. Kale S, Raja R, Thorat D, Gowrishankar S, Patil TV and Kundu GC: Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via α9β1 integrin. Oncogene. 2014 May 1;33(18):2295- 306. doi: 10.1038/onc.2013.184. Epub 2013 Jun 3.(I.F. 8.6) 26. Mishra R, Thorat D, SoundararajanG, PradhanSJ, ChakrabortyG, LohiteK, KarnikS and G C KunduGC: Semaphorin 3A upregulates FOXO 3a- dependent MelCAM expression leading to attenuation of breast tumor growth and angiogenesis. Oncogene. 2015 Mar 19;34(12):1584-95. doi: 10.1038/onc.2014.79. Epub 2014 Apr 14.(I.F. 8.6) 27. Ghosh S, Adhikary A, Chakraborty S, Bhattacharjee P, Mazumder M, Putatunda S, Gorain M, Chakraborty A, Kundu GC, Das T, Sen PC: Cross- talk between endoplasmic reticulum (ER) stress and the MEK/ERK pathway potentiates apoptosis in human triple negative breast carcinoma cells: role of a dihydropyrimidone, nifetepimine . J Biol Chem. 2015 Feb 13;290(7):3936-49. doi: 10.1074/jbc.M114.594028. Epub 2014 Dec 19.(I.F. 4.6) 28. Shravanti Mukherjee, Argha Manna, PushpakBhattacharjee, MinakshiMazumdar, ShilpiSaha, SamikChakraborty, DeblinaGuha, ArghyaAdhikary, Debarshi Jana, MahadeoGorain, Sanhita Mukherjee, G. C. Kundu,DiptendraSarkar and Tanya Das: Non-migratory tumorigenic intrinsic cancer stem cells ensure breast cancer metastasis by generation of CXCR4+ migrating cancer stem cells. Oncogene, 2016 Feb 29. doi: 10.1038/onc.2016.26. [Epub ahead of print].(I.F. 8.6) 29. Dhiraj Kumar, Santosh Kumar, MahadeoGorain, DeeptiTomar, Harshal S. Patil, NNV Radharani, TVS Kumar, Tushar V. Patil, H. V. Thulasiram and G. C. Kundu: Notch1-MAPK Signaling Axis Regulates CD133+ Cancer Stem Cell-Mediated Melanoma Growth and Angiogenesis. Journal of Investigative Dermatology, Volume 136, Issue 12, Pages 2462–2474, 2016: doi: 10.1016/j.jid.2016.07.024. [Epub ahead of print].(I.F. 6.9) 30. Kumar D, Gorain M, Kundu G, Kundu GC. Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma.Mol Cancer. 2017;16(1):7. doi:10.1186/s12943-016-0578-3.(I.F. 10.679) 31. Arindam Datta, Dishari Ghatak, Sumit Das, Taraswi Banerjee, Anindita Paul, Ramesh Butti, Mahadeo Gorain, Sangeeta Ghuwalewala, Anirban Roychowdhury, SK Kayum Alam, Pijush Das, Raghunath Chatterjee, Maitrayee Dasgupta, Chinmay Panda, Gopal Kundu, and Susanta Roychoudhury. p53 gain-of-function mutations increase Cdc7-dependent replication initiation. EMBO Rep. 2017 Sep 8.pii: e201643347. doi: 10.15252/embr.201643347 (I.F. 8.6) 32. Butti R, Das S, Gunasekaran VP, Yadav AS, Kumar D, Kundu GC. Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. Mol Cancer. 2018;17(1):34. doi:10.1186/s12943-018-0797- x. (I.F. 10.679) 33. DeeptiTomar, Amit S. Yadav, Dhiraj Kumar, GarimaBhadauriya, Kundu, GC:Non-coding RNAs as potential therapeutic targets in breast cancer. BBA- Gene Regulatory Mechanisms.2020 Apr;1863(4):194378. doi: 10.1016/j.bbagrm.2019.04.005.Available online 29 April 2019.(I.F. 4.599) 34. Yadav AS, Radharani NNV, Gorain M, Bulbule A, Shetti D, Roy G, Baby T, Kundu GC. RGD functionalized chitosan nanoparticle mediated targeted delivery of raloxifene selectively suppresses angiogenesis and tumor growth in breast cancer [published online ahead of print, 2020 May 6]. Nanoscale. 2020;10.1039/c9nr10673a. doi:10.1039/c9nr10673a. (I.F. 6.970)
List of patents:
(i) A. B. Mukherjee (Brookeville, MD, USA); G. C. Kundu (Maharashtra, India) and D. Panda (Montreal, Canada): 2002, Methods and compositions for treatment of restenosis. US Patent No. US 6,458,590 B1
(ii) Gopal C. Kundu, Amit S. Yadav, Mahadeo Gorain and Shamayita Roy. Stable Nanoparticles and its Pharmaceutical Composition. Indian Patent Application No. 201721036409
(iii) Janhavi Devrukhar, Rajendra Prasad, Barkha Singh; Deepak Singh Chauhan, Amit Singh Yadav, Mahadeo Gorain, Sumit Das, Rohit Srivastava, Gopal Chandra Kundu:A NANOHYBRID, ITS METHOD OF PREPARATION AND USE. Indian Patent Application No. 201921020693
(iv) Kundu, Gopal C.; WEBER, Georg F: A Novel Method for Detection of Cancer. Indian Patent Application No. 201821040459
(v) Rohit Srivastava, Rajendra Prasad, Janhavi R. Devrukhkar, Ram Krishn Gupta, Deepak S. Chauhan, Gopal C. Kundu, Mahadeo Gorain and Amit S. Yadav. Fluorescent Hollow Mesoporous Silica and Method of Preparation Thereof. Indian Patent Application Provisional No. 201821022718.
Projects:
1) “Determination of biofilm pharmaco dynamics of newly formulated, nano- conjugated antibiotics to optimize treatment and dosing of chronic, antibiotic- resistant biofilm”, Funded by ICMR, Govt. of India, 2020-2023. 2) ‘’Multipronged approach for pre-clinical assessment of novel curcumin formulations as drugs for breast cancer therapy’’, Funded by DBT, Govt. Of India, 2020-2023. 3) ‘’Multi-Omics analysis to decipher mechanism of hormone resistance in Breast cancer’’, Funded by DBT, Govt. Of India, 2017-2022.
Collaborators:
International
• Dr. Mathias Müsken, Helmholtz Centre for Infection Research, Germany • A/Prof. Gautam Sethi, National University of Singapore, Singapore • Prof. S. Weiss, Hannover Medical Center, Hannover, Germany • Prof. Bjarne Bogen, University of Oslo, Oslo, Norway • Dr. Rakesh N.Veedu, Murdoch University, Perth, Australia
National
• Prof. Rohit Srivastava, IIT-Bombay, Mumbai • Dr. Susanta Roychoudhury, Dr. Saroj Gupta Cancer Centre, Kolkata • Dr. Sudip Gupta, ACTREC &TMH, Mumbai • Prof. Rajesh Gacche, Dept. of Biotechnology, SP Pune University, Pune • Prof. Mrutyunjay Suar, Director, School of Biotechnology, KIIT-DU, Bhubaneswar • Dr. Srinivas Patnaik, Asso. Professor, School of Biotechnology, KIIT-DU, Bhubaneswar • Dr. Saroj Ranjan Sahoo, Surgical Oncologist, KIMS, KIIT DU, Bhubaneswar • Dr. Sandeep Mishra, Senior Scientist, Institute of Life Science (ILS), Bhubaneswar
Lab members:
Current members (at School of Biotechnology, KIIT University, Bhubaneswar)
Dr. Amit Singh Yadav, Ph.D. (DBT Research Associate)
Title of project: Multipronged approach for pre-clinical assessment of novel curcumin formulations as drugs for breast cancer therapy
Title of Ph.D. thesis: Studies on the effect of Cyclic RGD-peptide-nanoparticle conjugated Drug(s) on Tumor Growth and Angiogenesis in Breast Cancer
Ms. NNV Radharani (Ph.D. Scholar and Project JRF)
Title of Ph.D. thesis: Role of Tumor Associated Macrophages (TAMs) in Regulation of Cancer Stem Cells (CSCs)-mediated Breast Tumor Growth and Angiogenesis
Dr. Ramesh Butti (Research Associate)
Title of Ph.D. thesis: Studies on role of tumor-derived Osteopontin in trans- differentiation of resident fibroblasts into myofibroblasts to promote breast cancer progression.
Ms. Abhilipsa Das (Ph.D. Scholar)
Ms. Barnalee Mishra (Indo-German ICMR Project JRF)
Previous Members (at NCCS, Pune)
Ph.D. Awarded
1. Dr. Subha Philip, Bethesda, USA 2. Dr. Ganpati Mahabeleshwar, CWRU, Cleveland, USA 3. Dr. Riku Das, The Cleveland Clinic, Cleveland, USA 4. Dr. Hema Rangaswami, UCSD, San Diego, USA 5. Dr. Goutam Chakraborty, Sloan-Kettering Cancer Ct, NY, USA 6. Dr. Shalini Jain, MD Anderson Cancer Center, TX, USA 7. Dr. Mansoor Ahmed, Yale University, CT, USA 8. Dr. Reeti Behera, Moffitt Cancer Center, FL, USA 9. Dr. Vinit Kumar, The Wistar Institute, PA, USA 10. Dr. Priyanka Sharma, NIH, USA 11. Dr. Rajinder Kaur, ICGEB, New Delhi, India 12. Dr. Santosh Kumar, Georgetown University, USA 13. Dr. Smita Kale, South Western University, TX, USA 14. Dr. Remya Raja, IOB, Banglore, India 15. Dr. Rosalin Mishra, University of Cincinnati, USA 16. Dr. Dhiraj Kumar, MD Anderson Cancer Center, USA 17. Dr. Pompom Ghosh, The Cleveland Clinic, Cleveland, USA 18. Dr. Amit Singh Yadav, School of Biotechnology, KIIT University, India 19. Dr Ramesh Butti, School of Biotechnology, KIIT University, India
Present Ph. D. Students
1. Ms. Deepti Tomar 2. Mr. TVS Kumar 3. Ms. NNV Radharani 4. Mr. Nimma Ramakrishna 5. Mr. Sumit Das 6. Mr. Pinaki Banerjee
Ex N-PDF & RA
1. Dr. Vinoth Prasanna 2. Dr. Chinu Bhargava
Ex-Project JRF/SRF
1. Ms. Anuja Ramdasi 2. Ms. Dattatrya Shetti 3. Mr. Gaurab Roy 4. Ms. Thejus Baby 5. Ms. Priyanka Ghorpade 6. Ms. Monalisa Bandopadhyay 7. Mr. Shailesh K Bhalara 8. Ms. Shamayita Roy 9. Ms. Prachi Kapse 10. Ms. Garima Bhadauriya 11. Ms. Sakshi Thakur 12. Ms. Chaitali
PUBLICATIONS
1. Kundu GC and Sinha NK: Purification and characterization of proteinase inhibitor from artocarpus integrifolia seeds. Phytochemistry 28:725-728, 1989. (I.F. 2.27)
2. Sen S, Kundu GC, Castel J, Mekhail N, Misono KS and Healy B: Myotrophin: Purification of a novel peptide from spontaneously hypertensive rat heart that influences myocardial growth. J. Biol. Chem. 265 (27): 16635-16643, 1990. (I.F. 4.258)
3. Kundu GC and Misono KS: Affinity labeling of endothelin receptors in bovine and rat lung membranes by NÎ9- azidobenzoyl-125 I-endothelin-1. Mol. and Cell. Endocrinology 79: 85-92, 1991. (I.F. 3.859)
4. Kundu GC and Wilson IB: Identification of endothelin converting enzyme in bovine lung membranes using a new fluorogenic substrate. Life Sciences 50(13): 965-970, 1992. (I.F. 1.09)
5. Kundu GC and Wilson IB : Endothelin converting enzyme: the binding of metal ions. Int. J. Peptide and Protein Res. 42(1): 64-67, 1993. (I.F. 0.34)
6. Kundu GC, Schullek JR and Wilson IB: The alkylating properties of chlorambucil. Pharmacol. Biochem. Behav. 49(3): 621-624, 1994. (I.F. 2.87)
7. Kundu GC, Ji I, McCormick DJ, and Ji TH: Photoaffinity labeling of the lutropin receptor with synthetic peptide for carboxyl terminus of the human choriogonadotropin a subunit. J. Biol. Chem. 271(19): 11063-11066, 1996. (I.F. 4.258)
8. Kundu GC, Mantile G, Miele L, Cordela-Miele E and Mukherjee AB: Recombinant human uteroglobin suppresses cellular invasiveness via a novel class of high-affinity cell surface binding site. Proc. Natl. Acad. Sci. USA 93: 2915-2919, 1996. (I.F. 9.423)
9. Kundu GC and Mukherjee AB: Evidence that porcine pancreatic phospholipase A2 via its high-affinity receptor stimulates extracellular matrix invasion by normal and cancer cells. J. Biol. Chem. 272(04), 2346-2353, 1997. (I.F. 4.258)
10. Shanmugam V, Chackalaparampil I, Kundu GC, Mukherjee AB and Mukherjee BB: Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells. Biochemistry 36(19), 5729-5738, 1997. (I.F. 2.98)
11. Zhang Z, Kundu GC, Yuan C-J, Ward JM, Lee EJ, DeMayo F, Westphal H and Mukherjee AB: Severe fibronectin-deposit renal glomerular disease in mice lacking uteroglobin. Science 276,1408-1412, 1997. (I.F. 34.661)
12. Kundu GC, Panda D, Lee BI, Peri A, Fohl D, Chackalaparampil I, Mukherjee BB, Li XD, Mukherjee DC, Seides S, Rosenberg J, Stark K and Mukherjee AB: Potential roles
of osteopontin and avb3 integrin in the development of coronary artery restenosis after angioplasty. Proc. Natl. Acad. Sci. USA 94, 9308-9313, 1997. (I.F. 9.423)
13. Phang T, Kundu GC, Hong S, Ji I and Ji TH: The amino terminal region of the luteinizing hormone/choriogonadotropin receptor contacts both subunits of human choriogonadotropin: II Photoaffinity labeling. J. Biol. Chem. 273(22), 13841-13847, 1998. (I.F. 4.258)
14. Kundu GC, Mandal A, Zhang Z, Mantile-Selvaggi GandMukherjee AB: Uteroglobin suppresses extracellular matrix invasion by normal and cancer cells that express the high affinity UG-binding proteins. J. Biol. Chem. 273 (35), 22819-22824, 1998. (I.F. 4.258)
15. Mukherjee AB, Kundu GC, Mandal AK, Pattabiraman N, Yuan C-J and Zhang Z: Uteroglobin(UG): Physiological role in normal glomerular function, uncovered by targeted disruption of the UG gene in mice. Am. J. Kid. Dis. 32 (6), 1106-1120, 1998. (I.F. 0.81)
16. Kundu GC, Zhang Z, Panda D, Mandal A.K., Mantile-Selvaggi Peri A, Yuan C-J and Mukherjee AB: Loss of transformed phenotype in cancer cells by over expression of uteroglobin gene. Proc. Natl. Acad. Sci. USA 96, 3963-3968, 1999. (I.F. 9.423)
17. Mukherjee AB, Kundu GC, Mantile-Selvaggi G, Yuan C-J, Mandal AK, Chattopadhyay S, Zhang F,Pattabiraman N andZhang Z: Uteroglobin: A novel cytokine? Cell Mol Life Sci. 55(5), 771-87, 1999. (I.F. 5.694)
18. Kundu GC, Zheng F, Zhang Z, Ward JM, DeMayo F, Mukherjee AB: An essential role of uteroglobin in preventing immunoglobulin A-nephropathy in mice. Nature Medicine 5(9), 1018-1025, 1999. (I.F. 30.357)
19. Zheng F, Kundu GC, Zhang Z, Mukherjee AB, Ward J and DeMayo F: Identical glomerulopathy in two different mouse models of uteroglobin deficiency. Am. J. Kid.Dis. 35(2), 362-363, 2000 (I.F. 0.81)
20. Zhang Z, Kundu GC, Zheng F, Yuan C-J, Lee E, Westphal H, Ward J, DeMayo F
and Mukherjee AB: Insight into the physiological function(s) of uteroglobin by gene knockout and antisense-transgenic approaches. Annals of the New York Academy of Sciences. 923, 210-233, 2000. (I.F. 4. 518)
21. Choudhury B, Mantile-Selvaggi G, Kundu GC, Miele L, Cordella-Miele E, Zhang Z, Mukherjee AB: Amino acid residues in alpha-helix-3 of human uteroglobin are critical for phospholopase A2 inhibitory activity. Annals of the New York Academy of Sciences. 923, 307--311, 2000. (I.F. 4. 518)
22. Kundu GC, Zhang Z, Mantile-Selvaggi G, Mandal A, Yuan C-JandMukherjee AB: Uteroglobin binding proteins: regulation of cellular motility and invasion in normal and cancer cells. Annals of the New York Academy of Sciences. 923, 234-248, 2000. (I.F. 4. 518)
Publications from NCCS, Pune, India (2001-till date)
23. Philip S, Bulbule, A and Kundu GC: Osteopontin stimulates tumor growth and activation of pro-matrix metalloproteinase-2 through NF-kappa B mediated induction of membrane type 1-matrix metalloproteinase in murine melanoma cells. J. Biol. Chem. 276 (48), 44926-44935, 2001. (I.F. 4.6)
24. Annie Bligh SW, Bashall A, Garrud C, McPartlin M, Wardle N, White K, Padhye S, Barve V and Kundu GC: Reaction of (C-(6-aminomethyl-pyridin-2-yl)-methylamine) chloroplatinum (II) with nucleosides and its biological activity. Dalton Transaction, 2, 184-188, 2003. (I.F. 4.177)
25. Mahabeleshwar GH and Kundu GC: Syk, a protein tyrosine kinase, suppresses the cell motility and NF-kappa B mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3’-kinase activity in breast cancer cells. J. Biol. Chem. 278 (8), 6209-6221, 2003. (I.F. 4.6)
26. Philip S and Kundu GC: Osteopontin induces NF-kappa B mediated promatrix metalloproteinase-2 activation through IKK/I B signaling pathways and curcumin (diferulolylmethane) down regulates these pathways. J. Biol. Chem. 278 (16), 14487- 14497, 2003. (I.F. 4.6)
27. Takada Y, Mukhopadhyay A, Kundu GC, Mahabeleshwar GH, Singh S, and Aggarwal BB: Hydrogen peroxide activates NF- B through tyrosine phosphorylation of I B and serine phosphorylation of p65: Evidence for the involvement of I B kinase and Syk protein tyrosine kinase. J. Biol. Chem. 278 (26), 24233-24241, 2003. (I.F. 4.6)
28. Das R, Mahabeleshwar GH and Kundu GC: Osteopontin stimulates cell motility and NF- B mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J. Biol. Chem. 278 (31), 28593-28606, 2003. (I.F. 4.6)
29. Mahabeleshwar GH and Kundu GC: Tyrosine kinase, p56lck regulates cell motility and NF- B-mediated secretion of urokinase type plasminogen activator through tyrosine phosphorylation of I B following hypoxia/reoxygenation. J. Biol. Chem. 278 (52), 52598-52612, 2003. (I.F. 4.6)
30. Mahabeleshwar GH, Das R and Kundu GC: Tyrosine kinase, p56lck-induced cell motility andurokinase type plasminogen activator secretion involves activation of epidermal growth factor receptor/extracellular signal regulated kinase pathways. J. Biol. Chem. 279 (11), 9733-9742, 2004. (I.F. 4.6)
31. Philip S, Bulbule A and Kundu GC: Matrix metalloproteinase-2: mechanism and regulation of NF- B-mediated activation and its role in cell motility and ECM- invasion. Glycoconjugate J. 21, 429-441, 2004. (I.F. 1.9)
32. Das R, Mahabeleshwar GH and Kundu GC: Osteopontin induces AP-1-mediated secretion of urokinase type plasminogen activator through c-Src dependent EGF receptor transactivation in breast cancer cells. J. Biol. Chem. 279 (12), 11051-11064, 2004. (I.F. 4.3)
33. Rangaswami H, Bulbule A and Kundu GC: Nuclear factor inducing kinase plays crucial role in osteopontin induced MAPK/IKK dependent nuclear factor B-mediated promatrix metalloproteinase-9 activation. J. Biol. Chem. 279 (37), 38921-38935, 2004. (I.F. 4.3)
34. Sandbhor U, Kulkarni P, Padhye S, Kundu GC, Mackenzie G and Pritchard R: Antimelanomal activity of the copper (II) complexes of 1-substituted 5-amino imidazole ligands against B16F10 mouse melanoma cells. Bioorg. Med. Chem. Lett. 14(11), 2877-2882, 2004. (I.F. 2.5)
35. Das R, Philip S, Mahabeleshwar GH, Bulbule A and Kundu GC: Osteopontin: it’s role in regulation of cell motility and nuclear factor B-mediated urokinase type plasminogen activator expression. IUBMB Life 57 (6), 441-447, 2005. (I.F. 2.7)
36. Rangaswami H, Bulbule A and Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends in Cell Biol. 16 (2), 79-87, 2006. (I.F. 11.5)
37. Chakraborty G, Rangaswami R, Jain S, and Kundu GC: Hypoxia regulates crosstalk
between Syk and Lck leading to breast cancer progression and angiogenesis.J. Biol. Chem. 281 (16), 11322-11331, 2006. (I.F. 4.6)
38. Jain S, Chakraborty G and Kundu GC: The Crucial Role of cyclooxygenase-2 in osteopontin-induced PKCα/c-Src/IKKα/β dependent prostate tumor progression and angiogenesis. Cancer Res. 66 (13), 6638-6648, 2006. (I.F. 9.3)
39. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V and Kundu GC: The multifaceted roles of Osteopontin in cell signaling, tumor progression and angiogenesis. Curr. Mol. Med. 6 (8), 819-830, 2006. (I.F. 2.9)
40. Jain S, Chakraborty G, Bulbule A, Kaur R and Kundu GC: Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin. Ther. Targets11(1), 81-90, 2007. (I.F. 4.8)
41. Rangaswami H, Kundu GC.Osteopontin stimulates melanoma growth and lung metastasis through NIK/MEKK1-dependent MMP-9 activation pathways. Oncol. Rep. 18 (4):909-15, 2007. (I.F. 2.5)
42. Chakraborty et al. Osteopontin regulated signaling network in cancer: redefining the molecular targets. Intl. J. Mol. Med. 20 (Suppl 1), S75, 2007. (I.F. 2.3)
43. Chakraborty G, Jain S and Kundu GC:Osteopontin promotes VEGF dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 68 (1),152-161, 2008. (I.F. 9.3)
44. Chakraborty G, Jain S, Patil TV and Kundu GC:Down-Regulation of Osteopontin Attenuates Breast Tumor Progression in vivo. J. Cell. Mol. Med., 12 (6A), 2305- 2318, 2008. (I.F. 4. 9)
45. Chakraborty G, Jain S, Kale S, Raja R, Kumar S, Mishra R and Kundu GC: Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression. Mol Med Reports., 1 (5), 641-646, 2008 (selected for cover page).(I.F. 1. 67)
46. Jain S, Chakraborty G, Raja R, Kale S, and Kundu GC: Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res, 68(19):7750–7759, 2008. (I.F. 9.3)
47. Seth D, D'Souza El-Guindy NB, Apte M, Mari M, Dooley S, Neuman M, Haber PS, Kundu GC, Darwanto A, de Villiers WJ, Vonlaufen A, Xu Z, Phillips P, Yang S, Goldstein D, Pirola RM, Wilson JS, Moles A, Fernández A, Colell A, García-Ruiz C, Fernández-Checa JC, Meyer C, Meindl-Beinker NM. Alcohol, Signaling, and ECM Turnover.Alcohol Clin Exp Res. 34 (1), 4-18, 2010. (I.F. 2.9)
48. Behera R, KumarV, LohiteK, KarnikS and Kundu GC: Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells. Carcinogenesis, 31 (2), 192-200, 2010.(I.F. 4.9)
49. Ahmed M and Kundu GC: Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-kappa B dependent AP-1-mediated ICAM-1 expression in breast cancer cells. Molecular Cancer 9(1), 101, 2010. (I.F. 6.2)
50. Singh JP, Tamang S, Rajamohanan PR, Jima NC, Chakraborty G, Kundu GC, Gaikwad SM, Khan MI: Isolation, Structure, and Functional Elucidation of a Modified Pentapeptide, Cysteine Protease Inhibitor (CPI-2081) from Streptomyces Species 2081 that Exhibit Inhibitory Effect on Cancer Cell Migration. J. Med Chem, June 16, 2010. (I.F. 5.6)
51. Sharma P, Kumar S and Kundu GC: Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells. Molecular Cancer, July 7, 9(1), 178, 2010. (I.F. 6.2)
52. Pradhan S, Mishra R, Sharma P and Kundu GC: Quercetin and sulforaphane in combination suppress the melanoma progression through down regulation of matrix metalloproteinase-9. Experimental and Therapeutic Medicine, 1, 915-920, 2010. (I.F. 1.3)
53. Kumar V, Behera R, Lohite K, Karnik S and Kundu GC: p38 Kinase is Crucial for Osteopontin-induced Furin Expression that Supports Cervical Cancer Progression. Cancer Research, 70 (24), 10381-10391, 2010. (I.F. 9.3)
54. Bulbule A, Saraswati Sand Kundu GC: Status of research on matrix metalloproteinases (MMPs) in India. Expert Opin Ther Targets. 15(6):671-5, 2011 (I.F. 4.8)
55. Ahmed et al. Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets.15(9):1113-26, 2011. (I.F. 4.8)
56. Saraswati S– and Kundu GC et al: Therapeutic Targeting of Osteopontin in Breast Cancer Cells. Breast Cancer Cells/Book 3, ISBN 979-953-307-182-3, 2011.
57. Prakash M. et al. Hyaluronan-Binding Protein 1 (HABP1/p32/gC1qR) Induces Melanoma Cell Migration and Tumor Growth by NF-kappa B Dependent MMP-2 Activation through integrin αvβ3 interaction. Cellular Signalling, 2011. (I.F. 4.2)
58. Chakraborty et al: Semaphorin 3A Suppresses Tumor growth and metastasis in Mice melanoma Model. PLOS One,7(3):e33633, 2012. (I.F. 3.1)
59. Kumar et al: Andrographolide inhibits osteopontin expression and breast tumor growththrough down regulation of PI3 kinase/Akt signaling pathway. Current MolecularMedicine;12(8):952-66, 2012. (I.F. 2.9)
60. Kumar S, Sharma P, Kumar D, Chakraborty G, Gorain M and Kundu GC: Functional Characterization of Stromal Osteopontin in Melanoma Progression and Metastasis. PLOS One,8(7):e69116, 2013. (I.F. 3.1)
61. Thorat D, Sahu A, Behera R, Lohite K, Deshmukh, S, Mane A, Karnik, S, Doke, S and Kundu GC: Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers. Oncology Letters, 2013 (in press). (I.F. 1.5)
62. Syed A, Saraswati S, Kundu GC, Ahmad A: Biological synthesis of silver nanoparticles using the fungus Humicola sp. and evaluation of their cytoxicity using normal and cancer cell lines. Spectrochim Acta A Mol Biomol Spectrosc. 2013 May 25;114C:144-147. doi: 10.1016/j.saa.2013.05.030. [Epub ahead of print](I.F. 2.7)
63. Panda JJ, Kaul A, Kumar S, Alam S, Mishra AK, Kundu GC, Chauhan VS: Modified dipeptide-based nanoparticles: vehicles for targeted tumor drug delivery; Nanomedicine (Lond). 2013 Feb 12. [Epub ahead of print] (I.F. 4.9)
64. Haldar S, Kumar S, Kolet SP, Patil HS, Kumar D, Kundu GC, Thulasiram HV: One-pot fluorescent labeling protocol for complex hydroxylated bioactive natural products. J Org Chem. 2013 Oct 18;78(20):10192-202. doi: 10.1021/jo401559t. Epub 2013 Oct 10. (I.F. 4.8)
65. Taware R-----Kundu GC and Ahmed A et al: Isolation, purification and characterization of Trichothecinol-A produced by endophytic fungus Trichothecium sp. and its antifungal, anticancer and antimetastatic activities. Sustainable Chemical Processes, 2014.
66. Byagari K, Shanavas A, Rengan AK, Kundu GC, Srivastava R: Biocompatible amphiphilic pentablock copolymeric nanoparticles for anti- cancer drug delivery. J Biomed Nanotechnol. 2014 Jan;10(1):109-19. (I.F. 3.929)
67. Bandopadhyay M, ---Kundu GC et al: Osteopontin as a therapeutic target for cancer. Expert Opin Ther Targets. 2014 Aug;18(8):883-95. doi: 10.1517/14728222. 2014.925447. Epub 2014 Jun 4. Review. PMID: 24899149. (I.F. 4.8)
68. Salunke GR, Ghosh S, Santosh Kumar R, Khade S, Vashisth P, Kale T, Chopade S, Pruthi V, Kundu GC, Bellare JR, Chopade BA: Rapid efficient synthesis and characterization of silver, gold, and bimetallic nanoparticles from the medicinal plant Plumbago zeylanica and their application in biofilm control. Int J Nanomedicine. 2014 May 27;9 Suppl 1:2635-53. doi: 10.2147/IJN.S59834. eCollection 2014. (I.F. 4.4)
69. Raja R, Kale S, Thorat D, Gowrishankar S, Lohite K, Mane A, Karnik S, Kundu GC:Hypoxia driven osteopontin contributes to breast tumor progression through modulation of HIF1α-mediated VEGF dependent angiogenesis.Oncogene. 2014 Apr 17;33(16):2053-64. doi: 10.1038/onc.2013.171. Epub 2013 Jun 3. (I.F. 8.6)
70. Kale S, Raja R, Thorat D, Gowrishankar S, Patil TV and Kundu GC: Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor- associated macrophages leading to enhanced angiogenesis and melanoma growth via α9β1 integrin. Oncogene. 2014 May 1;33(18):2295-306. doi: 10.1038/onc.2013.184. Epub 2013 Jun 3. (I.F. 8.6)
71. Mishra R, Thorat D, SoundararajanG, PradhanSJ, ChakrabortyG, LohiteK, KarnikS and G C KunduGC: Semaphorin 3A upregulates FOXO 3a- dependent MelCAM expression leading to attenuation of breast tumor growth and angiogenesis. Oncogene. 2015 Mar 19;34(12):1584-95. doi: 10.1038/onc.2014.79. Epub 2014 Apr 14. (I.F. 8.6)
72. Ghosh S, Adhikary A, Chakraborty S, Bhattacharjee P, Mazumder M, Putatunda S, Gorain M, Chakraborty A, Kundu GC, Das T, Sen PC: Cross- talk between endoplasmic reticulum (ER) stress and the MEK/ERK pathway potentiates apoptosis in human triple negative breast carcinoma cells: role of a dihydropyrimidone, nifetepimine. J Biol Chem. 2015 Feb 13;290(7):3936-49. doi: 10.1074/jbc.M114.594028. Epub 2014 Dec 19. (I.F. 4.6)
73. Mishra R, Kumar D, Tomar D, Chakraborty G, Kumar S, Kundu GC: The potential of class 3 semaphorins as both targets and therapeutics in cancer. Expert Opin Ther Targets. 2015 Mar;19(3):427-42. doi: 10.1517/14728222.2014.986095. Epub 2014 Nov 29. (I.F. 4.8)
74. Nanjappa V, Renuse S, Sathe GJ, Raja R, Syed N, Radhakrishnan A, Subbannayya T, Patil A, Marimuthu A, Sahasrabuddhe NA, Guerrero-Preston R, Somani BL, Nair B, Kundu GC, Prasad TK, Califano JA, Gowda H, Sidransky D, Pandey A, Chatterjee A: Chronic exposure to chewing tobacco selects for overexpression of stearoyl-CoA desaturase in normal oral keratinocytes.Cancer Biol Ther. 2015Oct 30;16(11):1593-603. doi: 10.1080/15384047.2015.1078022. Epub 2015 Sep 21. (I.F. 2.9)
75. Ghosh S, More P, Derle A, Kitture R, Kale T, Gorain M, Avasthi A, Markad P, Kundu GC, Kale S, Dhavale DD, Bellare J, Chopade BA: Diosgenin Functionalized Iron Oxide Nanoparticles as Novel Nanomaterial Against Breast Cancer. J Nanosci Nanotechnol. 2015 Dec;15(12):9464-72. (I.F. 1.3)
76. Rustagi Y, Jaiswal HK, Rawal K, Kundu GC, Rani V: Comparative Characterization of Cardiac Development Specific microRNAs: Fetal Regulators for Future.PLoS One. 2015 Oct 14;10(10):e0139359. doi: 10.1371/journal.pone.0139359.(I.F. 3.1)
77. Shravanti Mukherjee, Argha Manna, Pushpak Bhattacharjee, Minakshi Mazumdar, Shilpi Saha, Samik Chakraborty, Deblina Guha, Arghya Adhikary, Debarshi Jana, Mahadeo Gorain, Sanhita Mukherjee, G. C. Kundu, Diptendra Sarkar and Tanya Das: Non-migratory tumorigenic intrinsic cancer stem cells ensure breast cancer metastasis by generation of CXCR4+ migrating cancer stem cells. Oncogene, 2016 Feb 29. doi: 10.1038/onc.2016.26. [Epub ahead of print]. (I.F. 8.6)
78. Dhiraj Kumar, Santosh Kumar, Mahadeo Gorain, Deepti Tomar, Harshal S. Patil, NNV Radharani, TVS Kumar, Tushar V. Patil, H. V. Thulasiram and G. C. Kundu: Notch1-MAPK Signaling Axis Regulates CD133+ Cancer Stem Cell-Mediated Melanoma Growth and Angiogenesis. Journal of Investigative Dermatology, Volume 136, Issue 12, Pages 2462–2474, 2016: doi: 10.1016/j.jid.2016.07.024. [Epub ahead of print]. (I.F. 6.9)
79. Dai X, Ahn KS, Wang LZ, Kim C, Deivasigamni A, Arfuso F, Um JY, Kumar AP, Chang YC, Kumar D, Kundu GC, Magae J, Goh BC, Hui KM, Sethi G: Ascochlorin enhances the sensitivity of doxorubicin leading to the reversal of epithelial-to-mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther. 2016 Oct 7. pii: molcanther.0391.2016. [Epub ahead of print] (I.F. 5.6)
80. Kumar D, Gorain M, Kundu G, Kundu GC: Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma. Mol Cancer. 2017 Jan 30;16(1):7. doi: 10.1186/s12943-016-0578-3. (I.F. 6.2)
81. Ghosh A, Dasgupta D, Ghosh A, Roychoudhury S, Kumar D, Gorain M, Butti R, Datta S, Agarwal S, Gupta S, Krishna Dhali G, Chowdhury A, Schmittgen TD, Kundu GC, Banerjee S:MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2: Cell Death Dis. 2017 Mar 30; 8(3): e2706. doi: 10.1038/cddis.2017.123 (I.F. 5.4)
82. Sweety A. Wadhwani1, Mahadeo Gorain2, Pinaki Banerjee2, Utkarsha U. Shedbalkar4, Richa Singh1, Kundu G C, Balu A Chopade: Green Synthesis of Selenium Nanoparticles using Acinetobacter sp. SW30: Optimization, Characterization and its Anti-cancer activity in Breast Cancer cells. Intl. J. Nanomedicine Sep 13;12:6841-6855. doi: 10.2147/IJN.S139212. eCollection 2017. (I.F. 4.4)
83. Arindam Datta, Dishari Ghatak, Sumit Das, Taraswi Banerjee, Anindita Paul, Ramesh Butti, Mahadeo Gorain, Sangeeta Ghuwalewala, Anirban Roychowdhury, SK Kayum Alam, Pijush Das, Raghunath Chatterjee, Maitrayee Dasgupta, Chinmay Panda, Gopal Kundu, and Susanta Roychoudhury. p53 gain-of-function mutations increase Cdc7-dependent replication initiation. EMBO Rep. 2017 Sep 8. pii: e201643347. doi: 10.15252/embr.201643347 (I.F. 8.6)
84. Kumar D, Haldar S, Gorain M, Kumar S, Mulani FA, Yadav AS, Miele L, Thulasiram HV, Kundu GC: Epoxyazadiradione suppresses breast tumor growth through mitochondrial depolarization and caspase-dependent apoptosis by targeting PI3K/Akt pathway.BMC Cancer. 2018 Jan 8;18(1):52. doi: 10.1186/s12885-017-3876-2.
85. Butti R, Das S, Gunasekaran VP, Yadav AS, Kumar D, Kundu GC: Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. Mol Cancer. 2018 Feb 19;17(1):34. doi: 10.1186/s12943- 018-0797-x. Review. (I.F. 10.69)
86. Amit S Yadav, Poonam R Pandey, Ramesh Butti, NNV Radharani, Shamayita Roy, Shailesh K Bhalara, Mahadeo Gorain, Kundu GC, Dhiraj Kumar: The biology and therapeutic implications of tumor dormancy and reactivation.Front Oncol. 2018 Mar 19;8:72. doi: 10.3389/fonc.2018.00072. eCollection 2018. Review.(I.F. 4.137)
87. Butti R, Kumar TV, Nimma R, Kundu GC: Impact of semaphorin expression on prognostic characteristics in breast cancer. Breast Cancer (Dove Med Press). 2018 May 31;10:79-88. doi: 10.2147/BCTT.S135753. eCollection 2018.
88. Prasad R, Chauhan DS, Yadav AS, Devrukhkar J, Singh B, Gorain M, Temgire M, Bellare J, Kundu GC, Srivastava R: A biodegradable fluorescent nanohybrid for photo-driven tumor diagnosis and tumor growth inhibition. Nanoscale. 2018 Oct 18;10(40):19082-19091. doi: 10.1039/c8nr05164j.(I.F. 6.970)
89. Butti R, Gunasekaran VP, Kumar TVS, Banerjee P, Kundu GC: Breast cancer stem cells: Biology and therapeutic implications. Int J Biochem Cell Biol. 2018 Dec 5;107:38-52. doi: 10.1016/j.biocel.2018.12.001. [Epub ahead of print](I.F. 3.144)
90. Deepti Tomar, Amit S. Yadav, Dhiraj Kumar, Garima Bhadauriya, Kundu, GC:Non-coding RNAs as potential therapeutic targets in breast cancer. Biochim Biophys Acta Gene Regul Mech. 2019 Apr 29:194378. doi: 10.1016/j.bbagrm.2019.04.005.(I.F. 4.599)
91. Sneha Mahalunkar, Amit Singh Yadav, Mahadeo Gorain, Vinay Pawar, Ranveig Braathen, Siegfried Weiss, Bjarne Bogen , Suresh W. Gosavi and Gopal C. Kundu.Functional Design of pH Responsive Folate Targeted Polymer Coated Gold Nanoparticles for Drug Delivery in Breast Cancer.Int J Nanomedicine. 2019 Oct 15;14:8285-8302. doi: 10.2147/IJN.S215142. eCollection 2019.(I.F. 4.471)
92. Ashwini Wali,Mahadeo Gorain,Satish Inamdar,Gopal Kundu,and Manohar Badiger: In Vivo Wound Healing Performance of Halloysite Clay and Gentamicin-Incorporated Cellulose Ether-PVA Electrospun Nanofiber Mats. ACS Applied Bio Materials, (in press), 2019
93. Ravindra Taware, Khushman Taunk, Totakura V. S. Kumar, Jorge A. M. Pereir, José S. Câmara, H. A. Nagarajaram, Gopal C. Kundu, Srikanth Rapole. Extracellular volatilomic alterations induced by hypoxia in breast cancer cells. Metabolomics. 2020 Jan 24;16(2):21. doi: 10.1007/s11306-020-1635-x.(I.F. 3.167)
94. Amit S. Yadav,N Naga Venkata Radharani, Mahadeo Gorain, Anuradha Bulbule, Dattatrya Shetti, Gaurab Roy, Thejus Baby and Gopal C. Kundu: RGD functionalized chitosan nanoparticle mediated targeted delivery of raloxifene selectively suppresses angiogenesis and tumor growth in breast cancer: Nanoscale, 2020;10.1039/c9nr10673a. doi:10.1039/c9nr10673a.(in press). (I.F. 6.970)
95. Rajendra Prasad, Nishant K. Jain, Amit S. Yadav, Deepak S. Chauhan, Janhavi Devrukhkar, Mukesh K. Kumawat, Shweta Shinde, Mahadeo Gorain, Avnesh S. Thakor, Gopal C. Kundu, João Conde, Rohit Srivastava: Stepwise Assembly of Multimode Liposomal Nanotheranostic Agent for Targeted In Vivo Bioimaging and Near Infrared Light Mediated Cancer Therapy. Communications Biology (in press), 2020
96. Sakshi Sikka; Muthu K Shanmugam; Kodappully Sivaraman Siveen; Tina H Ong; Jong Hyun Lee; Feng Li; Peramaiyan Rajendran; Shireen Vali; Taher Abbasi; Shweta Kapoor; Arunachalam Chinnathambi; Tahani Awad Alahmadi; Sulaiman Ali Alharbi; Alan Prem Kumar; Boon Cher Goh; Dhiraj Kumar; Gopal C Kundu; Lingzhi Wang; Kwang Seok Ahn; Kam Man Hui; Gautam Sethi: Attenuation of oncogenic transcription factors by diosgenin impedes tumorigenesis in transgenic mouse prostate model. Journal of Biomedical Science (submitted), 2020
97. Shalini Nath, Susmita Mondal, Ramesh Butti, Vinoth PrasannaGunasekaran, Gopal C. Kundu, Uttara Chatterjee, Aniket Halder, Chitra Mandal:. Desialylation of Sonic-Hedgehog by Neu2 Inhibits Its Association With Patched1 Reducing Stemness Properties in Pancreatic Cancer Sphere Cells. Cells (In Press), 2020
98. Sonika Chibh, Bibhav Katoch, Avneet Kaur, Farheen Khanam, Amit Singh Yadav, Manish Singh, Gopal C. Kundu, Bhanu Prakash, Jiban Jyoti Panda: Microfluidics Driven Self-assembled Single Amino Acid Based Smart Nanobowl Encapsulation System with pH Responsive Covering for on Demand Drug Delivery. Nano Today (Submitted), 2020.
99. Ramesh Butti, VinothPrasanna Gunasekaran, Ramakrishna Nimma, Gautam Kundu, Deepti Tomar, Anuradha Bulbule, Dhiraj Kumar, Anupama Mane, Satyajith Gill, Tushar Patil, Georg F. Weber, Gopal C. Kundu: Tumor- derived Osteopontin Drives the Resident Fibroblast to Myofibroblast Differentiation through Twist1 to Promote Breast Cancer Progression. Cancer Research (in preparation), 2020
100. Sonali Kamble, Kapil Patil, Shrikant Hese, Bhaskar Dawane, Jasoda Choudhari, Kumar TVS, Gopal C. Kundu and Rajesh Gacche: Chloroxylon swietenia (Roxb.) DC triggers intrinsic apoptotic pathway in MCF-7 cells and inhibits tumor xenograft growth in vivo. Pharmacological Reports (Submitted), 2020.
101. Rajendra Prasad , Amit Yadav , Mr. Nishant Jain , Mukesh Kumawat , N. N. Radharani , Mahadeo Gorain , Gopal Kundu , Rohit Srivastava. Ultrahigh penetration and retention of graphene quantum dot mesoporous silica nanohybrids for image guided tumor regression. Communications Materials (Submitted), 2020